Mesdopetam (IRL790)
Levodopa-Induced Dyskinesia (PD-LIDs)
Key Facts
About IRLAB Therapeutics
IRLAB Therapeutics is dedicated to transforming the lives of patients with Parkinson's disease through its innovative, data-driven discovery platform and focused clinical pipeline. The company's proprietary Integrative Screening Process (ISP) accelerates and de-risks drug discovery, having generated multiple clinical-stage candidates. With a Phase III-ready asset for dyskinesia and a strategic focus on the high-growth Parkinson's market, IRLAB is positioned to address significant unmet medical needs and create substantial value.
View full company profileAbout IRLAB Therapeutics
IRLAB Therapeutics is dedicated to transforming the lives of patients with Parkinson's disease through its innovative, data-driven discovery platform and focused clinical pipeline. The company's proprietary Integrative Screening Process (ISP) accelerates and de-risks drug discovery, having generated multiple clinical-stage candidates. With a Phase III-ready asset for dyskinesia and a strategic focus on the high-growth Parkinson's market, IRLAB is positioned to address significant unmet medical needs and create substantial value.
View full company profile